Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating intracerebral hemorrhage or stroke NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclo ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by reducing mic ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a product development services agreement with Renaissance Lakewood LLC (“Renaissance”), a leading Contract Development and Manufacturing Organization (CDMO) focused on nasal drug delivery. This collab ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do no ...

公司介绍 - 公司为Proactive，其金融新闻和在线广播团队为全球投资受众提供快速、易获取、信息丰富且可操作的商业和金融新闻内容 [2] - 公司新闻团队遍布全球主要金融和投资中心，在伦敦、纽约、多伦多、温哥华、悉尼和珀斯设有办事处和工作室 [2] - 公司是中小型股市场专家，也会让社区了解蓝筹股公司、大宗商品和更广泛的投资故事，内容能吸引积极的个人投资者 [3] 人员情况 - 编辑Angela Harmantas有超15年北美股票市场报道经验，尤其关注初级资源股，曾为多家领先行业出版物从多个国家进行报道，还曾从事投资者关系工作并为瑞典政府领导加拿大的外国直接投资项目 [1] 技术应用 - 公司一直积极采用技术，人类内容创作者经验丰富，团队可使用技术辅助和优化工作流程 [4] - 公司偶尔会使用自动化和软件工具，包括生成式AI，但所有发布内容均由人类编辑和创作，符合内容制作和搜索引擎优化最佳实践 [5] 报道领域 - 团队提供包括但不限于生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术等市场的新闻和独特见解 [3]

文章核心观点 公司宣布其研发的鼻内给药药物Foralumab登上知名新闻频道，该药物有望治疗中度阿尔茨海默病及其他神经退行性疾病，且公司在免疫疗法领域有创新技术和研发进展 [1][3] 公司动态 - 公司鼻内给药药物Foralumab登上知名新闻频道，节目展示了公司中度阿尔茨海默病扩大使用计划中首位患者的用药体验 [1] - 公司创始人之一评论称Foralumab有望减缓阿尔茨海默病进展并改善认知功能，新闻报道凸显其在神经退行性疾病领域的潜力 [3] - 公司鼻内给药Foralumab正在非活动性继发性进展性多发性硬化症患者中进行2a期随机、双盲、安慰剂对照、多中心、剂量范围试验 [6] 药物介绍 - Foralumab是一种全人抗CD3单克隆抗体，鼻内给药可刺激调节性T细胞，在动物模型和继发性进展性MS患者中验证了抑制小胶质细胞活化、调节神经炎症的疗效 [5][6] - Foralumab通过结合T细胞受体调节T细胞功能来抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有观察到该效果 [7] - 目前已有10名非活动性继发性进展性多发性硬化症患者在扩大使用计划中接受Foralumab治疗，6个月内均有病情改善或稳定，FDA允许额外20名患者加入该计划 [6] 公司优势 - 公司是临床阶段生物制药公司，采用创新药物递送技术开发免疫疗法，鼻内给药方式相比静脉给药在疗效、安全性和耐受性上有提升潜力 [8][9] - 公司鼻内给药Foralumab是目前唯一处于临床开发阶段的全人抗CD3单克隆抗体，已显示出良好安全性和临床反应，其免疫疗法技术已获专利并有多项申请待批 [7][9]

文章核心观点 - 蒂齐亚娜生命科学公司的鼻内给药药物福拉鲁单抗在新闻频道被报道，该药物为中度阿尔茨海默病患者带来希望，其通过调节免疫系统减少炎症，有望减缓疾病进展和改善认知功能 [2][3][4] 分组1：公司动态 - 蒂齐亚娜生命科学公司宣布其研究药物鼻内福拉鲁单抗在知名新闻频道亮相，节目突出了公司中度阿尔茨海默病扩大使用计划中首位患者的用药体验 [2] - 公司的鼻内福拉鲁单抗在非活动性继发性进展性多发性硬化症（na - SPMS）开放标签中期扩大使用（EA）计划中已给10名患者用药，6个月内所有患者病情均有改善或稳定，FDA允许额外20名患者加入该EA计划 [8] - 鼻内福拉鲁单抗正在非活动性继发性进展性多发性硬化症患者中进行2a期随机、双盲、安慰剂对照、多中心、剂量范围试验（NCT06292923），该试验于2023年11月开始筛选患者 [8][9] 分组2：药物介绍 - 福拉鲁单抗是一种全人抗CD3单克隆抗体，鼻内给药可刺激调节性T细胞，通过调节免疫系统减少炎症，抑制多种免疫细胞亚群的效应特征 [4][8][9] - 鼻内福拉鲁单抗可通过诱导调节性T细胞抑制小胶质细胞活化，调节神经炎症，这种治疗效果在动物模型和继发性进展性MS患者中得到验证 [6] - 鼻内福拉鲁单抗有望成为一种辅助疗法，解决抗淀粉样蛋白疗法未针对的阿尔茨海默病发病机制的主要因素 [7] 分组3：行业背景 - 小胶质细胞活化是包括阿尔茨海默病、继发性进展性多发性硬化症、肌萎缩侧索硬化症和帕金森病在内的神经退行性疾病的关键因素，阿尔茨海默病的认知功能障碍与tau蛋白积累和小胶质细胞活化有关，需要超越靶向淀粉样蛋白的疗法 [5] 分组4：公司概况 - 蒂齐亚娜生命科学公司是一家临床阶段的生物制药公司，利用变革性药物递送技术开发突破性疗法，其创新的鼻腔给药方法相比静脉给药在疗效、安全性和耐受性方面有改善潜力 [10] - 公司的领先候选药物鼻内福拉鲁单抗是目前唯一处于临床开发阶段的全人抗CD3单克隆抗体，在研究中已显示出良好的安全性和临床反应，其免疫疗法替代途径技术已获专利并有多项申请待批，有望实现广泛的产品线应用 [10]